Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 128c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of $0.87, $1.28 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $80 million versus the consensus estimate of $1.78 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Equinor ASA (ADR) (EQNR) PT Lowered to $37 at TD Cowen
• Morgan Stanley continues to recommend exposure to the broadening theme